medigraphic.com
Instituto Nacional de Salud Pública

2019, Número 3

<< Anterior Siguiente >>

salud publica mex 2019; 61 (3)


Detección temprana de cáncer de pulmón en México

Arroyo-Hernández M, Zinser-Sierra JW, Vázquez-García JC

Idioma: Español
Referencias bibliográficas: 33
Paginas: 347-351
Archivo PDF: 280.43 Kb.


RESUMEN

La detección temprana de cáncer pulmonar (CP) en población de alto riesgo tiene el potencial de diagnosticar la enfermedad en estadios tempranos y facilitar el tratamiento oportuno con el fin de disminuir la tasa de mortalidad. En México, como en otros países en vías de desarrollo, además del tabaquismo, la exposición al humo de leña se posiciona como uno de los principales factores de riesgo para desarrollar CP, lo cual no se ha considerado en estudios de tamizaje previamente publicados. Distintas interrogantes surgen en relación con quiénes son las personas que presentan un alto riesgo de desarrollar CP en América Latina, cuál es el costo-beneficio de poner en marcha un programa de detección oportuna de CP en México y cuáles son los obstáculos que los países de la región enfrentan para su implementación.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Arrieta O, Guzmán-De Alba E, Alba-López LF, Acosta-Espinoza A, Alatorre-Alexander J, Alexander-Meza JF et al. Consenso nacional de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Rev Invest Clin. 2013;65(supl1):S5-84.

  2. Arrieta O, Campos-Parra AD, Zuloaga C, Avilés A, Sánchez-Reyes R, Vázquez-Manríquez ME, et al. Clinical and pathological characteristics, outcome and mutational profiles regarding non–small-cell lung cancer related to wood-smoke exposure. J Thorac Oncol. 2012;7(8):1228-34. https://doi.org/10.1097/jto.0b013e3182582a93

  3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J Thorac Oncol. 2007;2(8):706- 14. https://doi.org/10.1097/jto.0b013e31812f3c1a

  4. National Lung Screening Trial Research Team. The National Lung Screening Trial: Overview and study design. Radiology. 2011;258(1):243-53. https://doi.org/10.1148/radiol.10091808

  5. Mazzone PJ, Silvestri GA, Patel S, Kanne JP, Kinsinger LS, Wiener RS, et al. Screening for lung cancer. Chest. 2018;153(4):954-85. https://doi. org/10.1016/j.chest.2018.01.016

  6. Arrieta O, Martínez-Barrera L, Treviño S, Guzmán E, Castillo-González P, Ríos-Trejo MA et al. Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: An open label phase II study. J Thorac Oncol. 2008;3(8):887-93. https://doi. org/10.1097/jto.0b013e31818026f6

  7. Hernández-Garduno E, Brauer M, Pérez-Neria J, Vedal S. Wood smoke exposure and lung adenocarcinoma in non-smoking Mexican women. Int J Tuberc Lung Dis. 2004;8(3):377-83.

  8. Tanoue LT, Tanner NT, Gould MK, Silvestri GA. Lung cancer screening. Am J Respir Crit Care Med. 2015;191(1):19-33. https://doi.org/10.1164/ rccm.201410-1777ci

  9. Wiener RS, Gould MK, Arenberg DA, Au DH, Fennig K, Lamb CR, et al. An Official American Thoracic Society/American College of Chest Physicians Policy Statement: Implementation of low-dose computed tomography lung cancer screening programs in clinical practice. Am J Respir Crit Care Med. 2015;192(7):881-91. https://doi.org/10.1164/rccm.201508-1671st

  10. Roberts H, Walker-Dilks C, Sivjee K, Ung Y, Yasufuku K, Hey A, et al. Screening high-risk populations for lung cancer: Guideline recommendations. J Thorac Oncol. 2013;8(10):1232-7. https://doi.org/10.1097/ jto.0b013e31829fd3d5

  11. Stram DO, Park SL, Haiman CA, Murphy SE, Patel Y, Hecht SS, et al. Racial/ ethnic differences in lung cancer incidence in the multiethnic cohort study: An update. J Natl Cancer Inst. 2019;djy206. https://doi.org/10.1093/ jnci/djy206

  12. Wood DE, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, et al. Lung Cancer Screening, Version 3. 2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(4):412-41. https://doi. org/10.6004/jnccn.2018.0020

  13. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. https://doi.org/10.3322/caac.21442

  14. Organización Panamericana de la Salud/Instituto Nacional de Salud Pública. Encuesta Global de Tabaquismo en Adultos. Mexico 2015. Washington, DC/Cuernavaca, Morelos, México:OPS/INSP, 2017. Disponible en: https://www.who.int/tobacco/surveillance/survey/gats/mex-report- 2015-spanish.pdf

  15. Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz/Instituto Nacional de Salud Pública/Comisión Nacional contra las Adicciones/ Secretaría de Salud. Encuesta Nacional de Consumo de Drogas, Alcohol y Tabaco 2016-2017: Reporte de tabaco. Ciudad de México: INPRFM, 2017. Disponible en: https://drive.google.com/file/d/1Iktptvdu2nsrSpMBMT4Fdq BIk8gikz7q/view

  16. Arrieta O, Quintana-Carrillo R, Ahumada-Curiel G, Corona-Cruz J, Correa-Acevedo E, Zinser-Sierra J, et al. Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico. Tob Induc Dis. 2015;12(1):25. https:// doi.org/10.1186/s12971-014-0025-4

  17. Kawai H, Tada A, Kawahara M, Nakai K, Maeda H, Saitou R, et al. Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer—A multicenter study. Lung Cancer. 2005;49(1):63-70. https://doi.org/10.1016/j.lungcan.2004.12.006

  18. Van der Aalst CM, Van den Bergh KAM, Willemsen MC, De Koning HJ, Van Klaveren RJ. Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial. Thorax. 2010;65(7):600-5. https://doi.org/10.1136/ thx.2009.133751

  19. dos Santos RS, Franceschini JP, Chate RC, Ghefter MC, Kay F, Trajano ALC, et al. Do current lung cancer screening guidelines apply for populations with high prevalence of granulomatous disease? Results from the First Brazilian Lung Cancer Screening Trial (BRELT1). Ann Thorac Surg. 2016;101(2):481-8.https://doi.org/10.1016/j.athoracsur.2015.07.013

  20. Raez LE, Cardona AF, Santos ES, Catoe H, Rolfo C, Lopes G, et al. The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. Lung Cancer. 2018;119:7-13. https://doi.org/10.1016/j.lungcan.2018.02.014

  21. Raez LE, Nogueira A, Santos ES, dos Santos RS, Franceschini J, Ron DA, et al. Challenges in lung cancer screening in Latin America. J Glob Oncol. 2018;4:1-10. https://doi.org/10.1200/jgo.17.00040

  22. Raez LE, Santos ES, Rolfo C, Lopes G, Barrios C, Cardona A, et al. Challenges in facing the lung cancer epidemic and treating advanced disease in Latin America. Clin Lung Cancer. 2017;18(1):e71-9. https://doi. org/10.1016/j.cllc.2016.05.003

  23. Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri- Guerra Y, Louis JS et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013;14(5):391-436. https://doi.org/10.1016/ s1470-2045(13)70048-2

  24. Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The international epidemiology of lung cancer: Latest trends, disparities, and tumor characteristics. J Thorac Oncol. 2016;11(10):1653-71. https://doi. org/10.1016/j.jtho.2016.05.021

  25. Raymakers AJN, Mayo J, Lam S, FitzGerald JM, Whitehurst DGT, Lynd LD. Cost-effectiveness analyses of lung cancer screening strategies using lowdose computed tomography: A systematic review. Appl Health Econ Health Policy. 2016;14(4):409-18. https://doi.org/10.1007/s40258-016-0226-5

  26. Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014;371(19):1793-802. https://doi.org/10.1056/nejmoa1312547

  27. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of low-dose CT screening according to the risk of lungcancer death. N Engl J Med. 2013;369(3):245-54. https://doi.org/10.1056/ nejmoa1301851

  28. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer. JAMA. 2012;307(22):2418. https://doi.org/10.1001/jama.2012.5521

  29. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med. 2007;13(3):361-6. https://doi.org/10.1038/ nm1556

  30. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. https://doi.org/10.1056/nejmoa1102873

  31. Saghir Z, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: Status after five annual screening rounds with low-dose CT. Thorax. 2012;67(4):296-301. https:// doi.org/10.1136/thoraxjnl-2011-200736

  32. Infante M, Cavuto S, Lutman FR, Brambilla G, Chiesa G, Ceresoli G, et al. A randomized study of lung cancer screening with spiral computed tomography. Am J Respir Crit Care Med. 2009;180(5):445-53. https://doi. org/10.1164/rccm.200901-0076oc

  33. Bianchi F, Nicassio F, Marzi M, Belloni E, Dall’Olio V, Bernard L, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011;3(8):495-503. https://doi.org/10.1002/emmm.201100154




2020     |     www.medigraphic.com